e-Therapeutics PLC (LON:ETX) said it has expanded its scientific advisory board with the appointment of Bill Harte and John Mattick.
Harte’s experience spans computational chemistry, structural biology and modelling, medicinal chemistry, product development and portfolio prioritisation as well as chief executive experience, and he currently serves as chief translational officer at the Case Western Reserve University School of Medicine in Ohio, advising and translating preclinical programs into patients.
Mattick, meanwhile, is a professor of RNA Biology at UNSW Sydney in Australia and previously worked as chief executive of Genomics England, executive director of the Garvan Institute of Medical Research in Sydney, director of the Institute for Molecular Biology at the University of Queensland, and director of the Australian Genome Research Facility.
The appointments follow the establishment of the scientific advisory board in May with the initial appointment of Paul Burke as chair following the company’s expansion into RNA interference as a therapeutic modality to pursue drug discovery outcomes.
“I am delighted to welcome Bill and John to the e-therapeutics scientific advisory board. We believe that their high calibre experience and guidance will be of significant value as the company progresses its strategy to achieve its future commercial goals”, Burke said in a statement.
“We are honoured and excited to have convened such a distinguished scientific advisory board. Paul, Bill and John all have considerable industry experience, and we look forward to their strategic advice and insight on transforming the drug discovery process as we continue to grow e-therapeutics whilst exploring new areas such as RNAi”, added e-Therapeutics executive chairman Ali Mortazavi.
The company’s shares were up 1.4% at 16.1p in early deals on Monday.